RESUMEN
GSK3335065 is an inhibitor of kynurenine monooxygenase (KMO) being developed for the treatment of acute pancreatitis. Healthy male volunteers were administered ascending doses of GSK3335065 or matched placebo as a single intravenous bolus injection to assess safety, tolerability, pharmacokinetics and pharmacodynamics. GSK3335065 displayed an apparent volume of distribution between 20.6 L and 44.6 L, a clearance between 0.462 L/h and 0.805 L/hr and a terminal half-life between 31.3 and 34.5 hr. In the single subject who received 1.3 mg GSK3335065, changes in tryptophan pathway metabolites were observed consistent with the changes seen in preclinical species suggesting that KMO enzyme activity was partially inhibited. However, a broad complex ventricular tachycardia was observed in this subject, which was judged to be a Serious Adverse Event (SAE) and resulted in early termination of the study. While development of GSK3335065 was subsequently discontinued, significant confounding factors hinder a clear interpretation that the tachycardia was directly related to administration of the compound.
Asunto(s)
Quinurenina , Pancreatitis , Enfermedad Aguda , Método Doble Ciego , Voluntarios Sanos , Humanos , Masculino , Oxigenasas de Función MixtaRESUMEN
OBJECTIVE: To evaluate in healthy volunteers the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) potential of GSK2647544, (a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor). METHODS: Study 1 was a single-blind, randomized, placebo-controlled, crossover study with healthy male volunteers randomized to receive single escalating oral doses (0.5 - 750 mg) of GSK2647544. Study 2 was a single-blind, randomized, placebo-controlled study with healthy volunteers randomized to receive repeat doses (80 mg) of GSK2647544. The drug-drug interaction of GSK2647544 with simvastatin was also evaluated in study 2. RESULTS: Across both studies GSK2647544 doses were generally well tolerated with no GSK2647544-related clinically significant findings. GSK2647544 was readily absorbed and its plasma concentration declined bi-exponentially with a terminal half-life ranging from 8 to 16 hours. Plasma exposure of GSK2647544 increased approximately dose-proportionally. There was GSK2647544 dose-dependent inhibition of plasma Lp-PLA2 activity, with a trough inhibition (12 hours after dose) of 85.6% after 7-day twice daily dosing. The administration of simvastatin concomitantly with GSK2647544 increased the overall exposure (area under the plasma concentration-time curve and maximum plasma concentration) of simvastatin and simvastatin acid by 3.6- to 4.3-fold and 1.5- to 3.1-fold, respectively. CONCLUSIONS: GSK2647544 was generally well tolerated and had a reasonable PK-PD profile. The clinically significant drug-drug interaction led to an early termination of study 2.â©.
Asunto(s)
1-Alquil-2-acetilglicerofosfocolina Esterasa/antagonistas & inhibidores , Éteres Fenílicos/efectos adversos , Pirimidinonas/efectos adversos , Adulto , Inhibidores del Citocromo P-450 CYP3A/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Femenino , Voluntarios Sanos , Humanos , Masculino , Éteres Fenílicos/farmacocinética , Éteres Fenílicos/farmacología , Pirimidinonas/farmacocinética , Pirimidinonas/farmacología , Simvastatina/farmacología , Método Simple CiegoRESUMEN
AIM: Characterization of the biliary disposition of GSK1325756, using a non-invasive bile sampling technique and spectrometric analyses, to inform the major routes of metabolic elimination and to enable an assessment of victim drug interaction risk. METHOD: Sixteen healthy, elderly subjects underwent non-invasive bile capture using a peroral string device (Entero-Test(®)) prior to and following a single oral dose of GSK1325756 (100 mg). The device was swallowed by each subject and once the weighted string was judged to have reached the duodenum, gallbladder contraction was stimulated in order to release bile. The string was then retrieved via the mouth and bile samples were analyzed for drug-related material using spectrometric and spectroscopic techniques following solvent extraction. RESULTS: Nuclear magnetic resonance spectroscopy (NMR) indicated that the O-glucuronide metabolite was the major metabolite of GSK1325756, representing approximately 80% of drug-related material in bile. As bile is the major clearance route for GSK1325756 (only 4% of the administered dose was excreted in human urine), this result indicates that uridine 5'-diphospho-glucuronosyltransferases (UGTs) are the major drug metabolizing enzymes responsible for drug clearance. The relatively minor contribution made by oxidative routes reduces the concern of CYP-mediated victim drug interactions. CONCLUSION: The results from this study demonstrate the utility of deploying the Entero-Test® in early human studies to provide information on the biliary disposition of drugs and their metabolites. This technique can be readily applied in early clinical development studies to provide information on the risk of interactions for drugs that are metabolized and eliminated in bile.
Asunto(s)
Bilis/metabolismo , Sistema Biliar/metabolismo , Interacciones Farmacológicas , Glucurónidos/análisis , Piperidinas/metabolismo , Sulfonas/metabolismo , Administración Oral , Anciano , Anciano de 80 o más Años , Femenino , Glucurónidos/metabolismo , Humanos , Espectroscopía de Resonancia Magnética , Masculino , Tasa de Depuración Metabólica , Preparaciones Farmacéuticas/metabolismo , Piperidinas/administración & dosificación , Valores de Referencia , Manejo de Especímenes/métodos , Sulfonas/administración & dosificaciónRESUMEN
AIM: To evaluate the non-invasive collection of bile from healthy human subjects for the qualitative characterization of the biliary disposition of a drug, using spectrometric techniques. METHODS: Twenty subjects underwent non-invasive bile capture using a peroral string test (Entero-Test) device prior to and following a single oral dose of simvastatin (80 mg). The device, consisting of a weighted gelatin capsule containing a highly absorbent nylon string, was swallowed by each subject with the proximal end of the string taped to the face. Once the weighted string was judged to have reached the duodenum, gallbladder contraction was stimulated in order to release bile. The string was then retrieved via the mouth, and bile samples were analysed for drug-related material using spectrometric and spectroscopic techniques following solvent extraction. RESULTS: Numerous metabolites of simvastatin were detected, and the major metabolites were consistent with those reported from studies where bile was collected using invasive techniques from patients dosed with [(14) C]-simvastatin. CONCLUSIONS: The results from this study demonstrate the utility of deploying the Entero-Test in human studies to provide structural information on biliary metabolites. This can be readily applied in drug development studies, including those in the target patient population and may eliminate the need for more invasive sampling techniques.
Asunto(s)
Anticolesterolemiantes/metabolismo , Ácidos y Sales Biliares/metabolismo , Bilis/metabolismo , Preparaciones Farmacéuticas/metabolismo , Simvastatina/metabolismo , Adulto , Anticolesterolemiantes/análisis , Ácidos y Sales Biliares/análisis , Sistema Biliar/metabolismo , Cromatografía Líquida de Alta Presión/métodos , Circulación Enterohepática , Femenino , Humanos , Espectroscopía de Resonancia Magnética , Masculino , Preparaciones Farmacéuticas/análisis , Juego de Reactivos para Diagnóstico , Valores de Referencia , Simvastatina/análisisRESUMEN
We report the case of a 45-year-old male patient who underwent autologous osteochondral autografting in the knee for osteochondritis dissecans. The patient required revision surgery 1 year postoperatively, which allowed histologic and mechanical characterization of the intrinsic healing response of the initial graft donor sites. Histologic examination showed heterogeneous areas of dense fibrous tissue, bone, and discrete areas of cartilage. Mechanical testing using a confined compression testing technique determined the equilibrium stiffness as 0.97 MPa. The majority of dense fibrous tissue and areas of bone are likely responsible for the observed increased stiffness. When performing osteochondral autografting, consideration must be given to the benefit afforded to improving the areas of cartilage injury with the potential morbidity associated with graft harvest at the donor sites.